Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    745.67
    +0.38 (+0.05%)
     

  • GBP/EUR

    1.1607
    -0.0076 (-0.65%)
     

  • GBP/USD

    1.2370
    -0.0068 (-0.55%)
     

  • Bitcoin GBP

    51,912.08
    +943.66 (+1.85%)
     

  • CMC Crypto 200

    1,375.64
    +63.01 (+4.80%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • DOW

    37,986.40
    +211.02 (+0.56%)
     

  • CRUDE OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD FUTURES

    2,406.70
    +8.70 (+0.36%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

Vectura Group appoints AstraZeneca executive as CEO

Reuters - UK Focus

June 24 (Reuters) - Respiratory drugs specialist Vectura Group Plc appointed AstraZeneca (NYSE: AZN - news) executive James Ward-Lilley as chief executive officer effective Oct. 1.

Ward-Lilley replaces Chris Blackwell, who will leave the company at the end of this month.

Ward-Lilley is currently vice president at AstraZeneca and responsible for respiratory, inflammation and autoimmunity strategy, which has included the recent acquisitions of Almirall's respiratory business and Pearl Therapeutics, Vectura said in a statement.

Trevor Phillips will continue as interim CEO from the end of June until Ward-Lilley joins the company, it added. (Reporting by Roshni Menon in Bengaluru; Editing by Anupama Dwivedi)